The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Goldman Sachs on January 28, 2025. The analyst firm set a price target for $7.50 expecting ADPT to fall to within 12 months (a possible -3.85% downside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Goldman Sachs, and Adaptive Biotechnologies maintained their neutral rating.

The last upgrade for Adaptive Biotechnologies Corp happened on December 21, 2022 when Piper Sandler raised their price target to $14. Piper Sandler previously had a neutral for Adaptive Biotechnologies Corp.

There is no last downgrade for Adaptive Biotechnologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on January 28, 2025 so you should expect the next rating to be made available sometime around January 28, 2026.

While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $5.50 to $7.50. The current price Adaptive Biotechnologies (ADPT) is trading at is $7.80, which is out of the analyst’s predicted range.